Showing 1621-1630 of 2223 results for "".
- PCA SKIN Launches At-Home Triple Exfoliation Peel Padshttps://modernaesthetics.com/news/pca-skin-launches-at-home-triple-exfoliation-peel-pads/2487305/PCA SKIN has launched Triple Exfoliation Peel Pads, an at-home peel treatment designed to support smoother, brighter, healthier-looking skin between professional treatments, according to a company announcement. The Scottsdale, Arizona-based brand said the product builds on more than 35 yea
- Solta Medical’s Thermage Receives China Trademark Recognitionhttps://modernaesthetics.com/news/solta-medicals-thermage-receives-china-trademark-recognition/2487286/Solta Medical, Bausch Health Companies Inc.’s aesthetic business, announced that Thermage has received AAA Well-Known Trademark Certification from the China Trademark Association. The certification is reserved for select brands in mainland China and recognizes Thermage’s brand reputation,
- Experts Discuss Microneedling and Acne Scar Management During Revance Virtual Desksidehttps://modernaesthetics.com/news/experts-discuss-microneedling-and-acne-scar-management-during-revance-virtual-deskside/2487258/Acne scarring remains a common concern even after active acne resolves, according to speakers during a virtual deskside hosted by Revance, with discussion centering on microneedling and the SkinPen device for facial acne scar treatment. Modern Aesthetics Editorial Board member Suneel Chilu
- FDA Clears Caliway’s Phase 3 CBL-514 Trial for Abdominal Fat Reductionhttps://modernaesthetics.com/news/fda-clears-caliways-phase-3-cbl-514-trial-for-abdominal-fat-reduction/2487183/Caliway Biopharmaceuticals announced that the US Food and Drug Administration (FDA) cleared the Investigational New Drug application for CBL-0302, also known as SUPREME-02, its second global pivotal phase 3 study of CBL-514 for abdominal subcutaneous fat reduction.1 The IND pass
- SCALE 2026: Ipsen Reports Phase 2 Corabotase Data in Glabellar Lineshttps://modernaesthetics.com/news/scale-2026-ipsen-reports-phase-2-corabotase-data-in-glabellar-lines/2487141/Ipsen presented late-breaking Phase 2 data for corabotase, its investigational recombinant neuroinhibitor, in moderate-to-severe glabellar lines at the 2026 SCALE Symposium in Nashville, Tennessee. The study included 183 patients. At week 4, 66% of patients treated with corabotase 50 ng ac
- Aesthetic Meet 2026: The Aesthetic Society Names Dr. Jamil Ahmad Presidenthttps://modernaesthetics.com/news/aesthetic-meet-2026-the-aesthetic-society-names-dr-jamil-ahmad-president/2487120/The Aesthetic Society has named Jamil Ahmad, MD, as its President, and The Aesthetic Foundation has named David A. Sieber, MD, as President, during The Aesthetic MEET 2026 in Boston. Dr. Ahmad assumes leadership as The Society reports membership growth of more than 30%, with new members fr
- SCALE 2026: Dermatologists Navigate the Expanding Role of GLP-1 RAs in Skin Health and Aesthetic Carehttps://modernaesthetics.com/news/scale-2026-dermatologists-navigate-the-expanding-role-of-glp-1s-in-skin-health-and-aesthetic-care/2487119/Dermatologists Navigate the Expanding Role of GLP-1 RAs in Skin Health and Aesthetic Care As use of GLP-1 receptor agonists (RAs) continues to surge, dermatologists are increasingly encountering the downstream effects of these medications in both medical and cosmetic pract
- Rapalogix Health Launches Re-Q Pro-Longevity Serum with Focus on Cellular Skin Aginghttps://modernaesthetics.com/news/rapalogix-health-launches-re-q-pro-longevity-serum-with-focus-on-cellular-skin-aging/2487003/Rapalogix Health has introduced its new Re-Q Pro-Longevity Face Serum during a virtual launch event on Thursday, May 7, featuring co-Founder and board-certified dermatologist Doris Day, MD, and co-Founder and CEO Rahul Mehta. The webinar focused on the science behind the product and the company’s
- Review Examines Dermatologic Effects of Rapid Weight Losshttps://modernaesthetics.com/news/review-examines-dermatologic-effects-of-rapid-weight-loss/2486984/Rapid weight loss associated with bariatric surgery, glucagon-like peptide-1 receptor agonists (GLP-1 RA), and intensive lifestyle interventions may contribute to dermatologic and structural changes that extend beyond reduced body size, according to a narrative rev
- Aesthetic Record Acquires JOYA Health to Expand Employer-Linked Skin Care Accesshttps://modernaesthetics.com/news/aesthetic-record-acquires-joya-health-to-expand-employer-linked-skin-care-access/2486904/Aesthetic Record, a widely used electronic medical record (EMR) and practice management platform in aesthetics, has announced its acquisition of JOYA Health, a company focused on employer-sponsored skin health benefits. The transaction underscores a broader trend toward specialized, consumer-driv